Syncona Limited Appointment of Chair-Designate and NED (0017B)
June 04 2019 - 2:00AM
UK Regulatory
TIDMSYNC
RNS Number : 0017B
Syncona Limited
04 June 2019
Syncona Limited
Melanie Gee Appointed Non-Executive Director and
Chair-designate
4 June 2019
Syncona Limited, a leading healthcare company focused on
founding, building and funding global leaders in life science,
announces that Melanie Gee has been appointed to the Group's Board
of Directors as a Non-Executive Director and Chair-designate with
immediate effect. Melanie will also join the Nomination and
Remuneration Committees, and will work closely with current Chair
Jeremy Tigue over the coming months in preparation for his
retirement and handover of the Chair on 31 December 2019. The
appointment process was led by Nicholas Moss, the Company's Senior
Independent Director.
Melanie is an accomplished investment banker with over 30 years'
experience in the financial advisory industry. She is currently a
Non-Executive Director of Standard Life Aberdeen plc, alongside her
role as a Senior Advisor for Lazard & Co Limited, the London
office of Lazard Ltd, the NYSE-listed financial advisory and asset
management firm. She joined Lazard in 2008 after 25 years at UBS
Investment Bank where she led banking teams on substantial
transactions of many longstanding UBS clients.
Melanie has FTSE 100 and 250 Board experience which includes
membership of the Risk & Capital, Nomination & Governance,
Audit, Remuneration and Investment Committees. Prior Board
appointments include the position of Non-Executive Director of The
Weir Group from 2011 to 2017 and Non-Executive Director of Drax
Group from 2013 to 2016.
Nicholas Moss, Senior Independent Director, said, "We are very
pleased to announce the appointment of Melanie to the Board of
Syncona Limited and as Chair-designate today as part of our Board
succession planning process. Melanie will be a strong addition to
our Board and we look forward to working with her to continue our
strategy of investing in exceptional science whilst striving to
deliver transformational treatments to patients."
Jeremy Tigue, Chairman of Syncona Limited, "I am delighted to
welcome Melanie Gee to the Board. She has a wealth of expertise
built from 30 years in investment banking and is an experienced
board member, serving on the boards of both FTSE 100 and 250
companies. I have been greatly privileged to Chair the Company
through seven exciting years since its foundation in 2012 and look
forward to handing over to Melanie at the end of December."
Melanie Gee said, "I am very much looking forward to joining the
Syncona Board and engaging with its talented management team to
help deliver their strategic objectives. It is an exciting time for
the Company and I am pleased to have the opportunity to be part of
that as it builds on its impressive momentum of creating successful
life sciences companies."
No further details are required to be disclosed under LR
9.6.13
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay / Siobhan Weaver
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Ben Atwell / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Ltd. These statements and forecasts involve
risk and uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements and forecasts. Nothing in this
announcement should be construed as a profit forecast.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASSSFWDFUSEDM
(END) Dow Jones Newswires
June 04, 2019 02:00 ET (06:00 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024